Harnessing post-translational modifications for a tuberculosis booster vaccine

FHS
June 19, 2024
4:26 pm

Tuberculosis is still one of the deadliest infectious diseases, causing over one million deaths each year worldwide.

Gilead axes PhIII trial for CD47 drug in latest setback for $4.9B buyout

Gilead will scrap one of three Phase III trials for magrolimab, the anti-CD47 drug at the heart of its $4.9 billion acquisition of Forty Seven

July 25, 2023

Coated textiles could be used as antimicrobial curtains in hospitals

Hospital germs and pathogens are not always transmitted directly from person to person. They can also spread via germ-contaminated surfaces and objects

November 29, 2023

FDA advisory panel signals lack of confidence in data on Amgen’s cancer drug

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday. Regulatory

October 5, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.